Search clinical trials for: BTK Degrader

Total 325 results

Brian Jonas
National Cancer Institute (NCI); Celgene; Pharmacyclics LLC.

Completed

Ibrutinib and Lenalidomide in Treating Patients With Myelodysplastic Syndrome

Previously Treated Myelodysplastic Syndrome | Myelodysplastic Syndrome | Therapy-Related Myelodysplastic Syndrome | Secondary Myelodysplastic Syndrome | Refractory High Risk Myelodysplastic Syndrome

United States
Steven E. Coutre

Completed

Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL

Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma

United States
AstraZeneca
Acerta Pharma BV

Completed

Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19. (CALAVI)

COVID-19

Italy, Turkey, Brazil, Japan, South Africa, Germany, Poland, Russian Federation, India, Peru, France, Argentina, Chile, Mexico
AstraZeneca
Acerta Pharma BV

Completed

Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19. (CALAVI US)

COVID-19

United States
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate...

Completed

Effect of Hepatic Impairment on M2951 (BTK Inhibitor) PK

Hepatic Impairment

Germany
Acotec Scientific Co., Ltd

Completed

AcoArt Ⅱ/ BTK China: Drug-eluting Balloon for Below-The-Knee Angioplasty Evaluation in China

Peripheral Artery Disease

China
Philips Clinical & Medical Affairs Global

Completed

Tack Optimized Balloon Angioplasty Below the Knee (TOBA - BTK) Study (TOBABTK)

Peripheral Artery Disease | Critical Limb Ischemia

Austria
Biogen

Completed

A Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of BIIB091, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Healthy Adult Participants

Healthy Volunteer

United States
Pharmacyclics LLC.
Janssen Research & Development, LLC

Completed

Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia

Waldenström's Macroglobulinemia

United States, Spain, France, Canada, Germany, Italy, Australia, United Kingdom, Greece
AstraZeneca
Acerta Pharma, LLC

Completed

A Study to Evaluate Relative Bioavailability, Proton Pump Inhibitor (PPI) (Rabeprazole) Effect, Food Effect and Particle Size Effect of New Acalabrutinib Tablet in Healthy Subjects

Bioavailability | B-cell Lymphoid Cancer

United States
Cagent Vascular LLC

Completed

The PRELUDE BTK Study

Peripheral Arterial Disease | Critical Limb Ischemia

New Zealand, Austria, Germany, Poland
Novartis

Completed

Efficacy, Safety and Tolerability of Agomelatine in the Prevention of Relapse of Major Depressive Disorder

Major Depressive Disorder

United States
Zhejiang DTRM Biopharma

Completed

Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas

Chronic Lymphocytic Leukemia | B-Cell Lymphoma

United States
Acerta Pharma BV
Acerta Pharma, LLC

Completed

An Open-Label, Phase 1b Study of Acalabrutinib With and Without Dexamethasone in Subjects With Multiple Myeloma

Multiple Myeloma (MM)

United States, United Kingdom
Zhejiang DTRM Biopharma

Completed

Safety, Tolerability and PK of BTK Inhibitor DTRMWXHS-12 in Patients With B-Cell Lymphomas

Chronic Lymphocytic Leukemia | B-cell Lymphomas

China
M.D. Anderson Cancer Center
Pharmacyclics LLC.

Completed

Pilot Study to Determine Effects of the Btk Inhibitor PCI-32765 on Leukemia Cell Kinetics and Trafficking, Using Heavy Water Labeling in Subjects With CLL and SLL

Leukemia

United States
Dana-Farber Cancer Institute
Eli Lilly and Company

Withdrawn

ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies

Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia
Ospedale San Donato

Completed

Evaluation of the Use of ACOTEC Drug-Eluting Balloon Litos ® in Below-The-Knee Arteries to Treat Critical Limb Ischemia (ACOART-BTK)

Peripheral Artery Disease

Italy
C. R. Bard

Completed

Registry Investigating the Clinical Use and Safety of the Lutonix Drug Coated Balloon for Treatment of BTK Arteries (BTKRegistry)

Peripheral Artery Disease

Austria, Belgium, France, Switzerland, Germany, Italy, Greece, Spain, United Kingdom, Portugal, Saudi Arabia
Janssen-Cilag International NV

Withdrawn

A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant Depression

Depressive Disorder, Treatment-Resistant
Celgene
The Leukemia and Lymphoma Society

Completed

Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia

Waldenstrom Macroglobulinemia | Chronic Lymphocytic Leukemia | B Cell Non-Hodgkin's Lymphoma

United States
Parkview Health
Biotronik, Inc.

Completed

Engaging Patients in Heart Failure Management

Congestive Heart Failure

United States
Emory University
Novartis

Terminated

Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Ibrutinib Plus Rituximab and Lenalidomide in Treating Elderly Participants With Newly Diagnosed Mantle Cell Lymphoma

Mantle Cell Lymphoma | CCND1 Positive | CD20-Positive Neoplastic Cells Present
Korea University Guro Hospital

Completed

Self-Expanding Nitinol Stent Versus Balloon Angioplasty Alone for the Below The Knee Arteries(SENS-BTK) (SENS-BTK)

Critical Limb Ischemia | Infrapopliteal Arterial Occlusive Disease

Korea, Republic of
Janssen Pharmaceutical K.K.

Completed

A Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Treatment-naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Lymphocytic Leukemia

Japan
Kami Maddocks
National Cancer Institute (NCI)

Completed

Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Mantle Cell Lymphoma | Recurrent Burkitt Lymphoma | Recurrent... and other conditions

United States
Second Affiliated Hospital of Soochow University

Unknown

the Efficacy and Safety of Agomelatine in the Patients With Parkinson's Disease

Depression | Parkinson Disease | Sleep Disorders | Circadian Rhythm Disorders
Proteon Therapeutics

Completed

Safety/Feasibility of Vonapanitase Following Angioplasty for Patients With Peripheral Artery Disease (PAD) Below the Knee (BTK)

Peripheral Artery Disease

United States
The University of New South Wales

Terminated

The ABSORB Bioresorbable Scaffold Below the Knee (BTK) Study

Ischemia | Arterial Occlusive Diseases | Peripheral Arterial Disease (PTA

New Zealand, Australia, Netherlands
Abbott Medical Devices

Terminated

The ABSORB BTK (Below The Knee) Clinical Investigation

Atherosclerosis | Peripheral Arterial Occlusive Disease | Peripheral Vascular Disease | Peripheral Artery Disease | Claudication | Critical Limb Ischemia | PAD | PVD | Lower Limb Disease | PAOD

Belgium
Vilnius University

Unknown

Measurement of Revascularization Effect Using NIRS in BTK Arteries

Wound Heal | Percutaneous Transluminal Angioplasty | Ischemic Feet

Lithuania
M.D. Anderson Cancer Center
Amgen; Pharmacyclics LLC.

Terminated

Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma

Lymphoma

United States
Vascuros Medical Pte Ltd
Novella Clinical

Unknown

The VaSecure BTK Study

Peripheral Arterial Occlusive Disease | Peripheral Vascular Disease | Peripheral Artery Disease

Singapore, Belgium, Germany
The Lymphoma Academic Research Organisation
Janssen Pharmaceutica N.V., Belgium

Terminated

Bruton's Tyrosine Kinase (BTK) Inhibition in B-cell Lymphomas (BIBLOS)

B-cell Lymphoma

France, Belgium
Jason Robert Gotlib
National Cancer Institute (NCI)

Terminated

Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis

Systemic Mastocytosis | Mast Cell Leukemia | Aggressive Systemic Mastocytosis

United States
Nanfang Hospital of Southern Medical University

Enrolling by invitation

Combination of BTK Inhibitor Overcomes Drug-resistance in Refractory/Relapsed FLT3 Mutant AML

Acute Myeloid Leukemia | FLT3-ITD Mutation | Brutons Tyrosine Kinase

China
Esanex Inc.

Withdrawn

Safety and Activity of SNX-5422 Plus Ibrutinib in CLL

Cancer

United States
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Safety and Efficacy Study of M2951 in Participants With Rheumatoid Arthritis

Rheumatoid Arthritis

United States, Germany
Assistance Publique - Hôpitaux de Paris
Boston Scientific Corporation

Unknown

An Efficacy and Safety Study to Evaluate Ranger DEB for BTK Angioplasty in Patients With CLI (RANGER-BTK) (RANGER-BTK)

Peripheral Vascular Diseases | Lower Limb Ischemia

France
Steven E. Coutre
National Cancer Institute (NCI)

Terminated

Ibrutinib, Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Adult Acute Myeloid Leukemia

United States
The Lymphoma Academic Research Organisation
Celgene Corporation

Completed

A Phase IB Study Of The BTKi CC-292 Combined With Lenalidomide In Adults Patients With Relapsed/Refractory B-Cell Lymphoma (CLEAR)

Relapsed/Refractory B-cell Lymphoma

France
Mayo Clinic
National Cancer Institute (NCI)

Withdrawn

Ibrutinib With or Without Bortezomib and Dexamethasone in Treating Patients With Relapsed or Refractory Immunoglobulin Light Chain Amyloidosis

Amyloidosis | Immunoglobulin Light Chain Deposition
Medtronic Endovascular

Completed

Study of IN.PACT Amphirion™ Drug Eluting Balloon vs. Standard PTA for the Treatment of Below the Knee Critical Limb Ischemia (INPACT-DEEP)

Critical Lower Limb Ischemia

Germany, Belgium, Netherlands, Switzerland, Austria, Italy
Janssen Pharmaceutical K.K.
Pharmacyclics LLC.

Completed

A Study to Evaluate the Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Patients With Recurrent Mature B-Cell Neoplasms

Recurrent Mature B-cell Neoplasms

Japan
National Cancer Institute (NCI)

Completed

Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | CD20 Positive

United States
Pharmacyclics LLC.
Janssen Research & Development, LLC

Completed

Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, Australia, Belgium, Canada, China, Czechia, Ireland, Israel, Italy, New Zealand, Poland, Russian Federation, Spain, Turkey, Ukraine, United Kingdom
Shockwave Medical, Inc.

Completed

Safety and Feasibility of the Shockwave Lithoplasty® System for the Treatment of Peripheral Vascular Stenosis (BTK)

Peripheral Arterial Disease

New Zealand, Austria, Germany
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

MSC2364447C Phase 1b in Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic

United States, Bulgaria
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant

Recurrent Small Lymphocytic Lymphoma | Prolymphocytic Leukemia | Recurrent Non-Hodgkin Lymphoma | Recurrent Chronic Lymphocytic Leukemia

United States

Search clinical trials for: BTK Degrader

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Serbia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations